Axsome Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Axsome Therapeutics has a total shareholder equity of $144.0M and total debt of $178.7M, which brings its debt-to-equity ratio to 124.1%. Its total assets and total liabilities are $545.7M and $401.7M respectively.
Key information
124.1%
Debt to equity ratio
US$178.69m
Debt
Interest coverage ratio | n/a |
Cash | US$331.44m |
Equity | US$144.04m |
Total liabilities | US$401.69m |
Total assets | US$545.73m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 19X's short term assets ($460.5M) exceed its short term liabilities ($144.0M).
Long Term Liabilities: 19X's short term assets ($460.5M) exceed its long term liabilities ($257.6M).
Debt to Equity History and Analysis
Debt Level: 19X has more cash than its total debt.
Reducing Debt: 19X's debt to equity ratio has increased from 111.4% to 124.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 19X has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 19X has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.